Committed to
Advancing transformative
therapies in hematologic cancers
Research and academic development behind GYA01
Founded in 2020 as a spin-off of Hospital Clínic Barcelona and the August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Gyala Therapeutics is building on the extensive experience of these pioneering institutions in CAR-T, having treated more than 500 patients with these therapies.
Gyala exemplifies how company creation by experienced investors, building on academic excellence, can translate breakthrough science into clinical innovation.
Nearly 1.3 million people worldwide are diagnosed each year with hematologic malignancies
Preclinical evidence supports the development of GYA01, Gyala’s investigational CAR-T cell therapy for the treatment of acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia (T-ALL), two diseases associated with significant unmet medical need (Leukemia, 2025).
